Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Arrowhead Pharma (NASDAQ:ARWR) but reduced the price target from $40 to $37.
November 30, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Arrowhead Pharma and lowered the price target from $40 to $37.
The reduction in price target by a major analyst like Morgan Stanley can lead to a negative perception among investors, potentially causing a short-term dip in ARWR's stock price. However, since the rating remains unchanged at Equal-Weight, the impact may be moderate rather than severe.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100